Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J50:127, 1983
2.
Davies MJ, Thomas AC. Plaque fissuring: The cause of acute myocardial infarction. sudden ischemic death and crescendo angina. Br Heart J53:363, 1985
3.
Shah PK, Forrester JS. Pathophysiology of acute coronary syndromes. Am J Cardiol68:16C, 1991
4.
Femandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol23:1562, 1994
5.
Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: Parts I and 2. N Engl J Med326:242, 310, 1992
6.
Fuster V, Badimon L, Bademon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute ischemic syndromes. N Engl J Med326:310, 1992
7.
Smith SH, Geer JC. Morphology of saphenous vein-coronary artery bypass grafts. Arch Pathol Lab Med107:13, 1983
8.
Walts AE. Fishbein MC, Matloff JM.Thrombosed. ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: Ten years' experience. Am Heart J114:718, 1987
9.
Giroud D, Li JM, Urban P, Meier B, Rutishauser W. Relation of the site of infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol69:729, 1992
10.
Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid. macrophage and smooth muscle cell content. Br Heart J69:377, 1993
11.
Davies MJ. Thrombosis in acute myocardial infarction and sudden death. In Mehta JL, Conti CR (eds). Thrombosis and platelets in myocardial ischemia HIP. FA Davis, Philadelphia, pp. 151-159, 1987
12.
Falk E. Dynamics in thrombus formation in plasminogen activation in fibrinolysis, in tissue remodeling, and in development. Ann NY Acad Sci667:204, 1992
13.
Chesebro JH, Badimon JJ, Badimon L, Fuster V. Anticoagulant and antiplatelet therapy in acute coronary syndromes and atrial fibrillation. Cardiol Rev1:167, 1993
14.
Stubbs MT, Bode W. A player of many parts: Spotlight falls on thrombin structure. Thromb Res69:1, 1993
15.
Vu TH, Hung DT, Wheaton VT, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell64:1057, 1991
16.
Aspirin as a therapeutic agent in cardiovascular disease. American Heart Association. Monograph 1993
17.
Patrono C. Aspirin as an antiplatelet drug. N Engl J Med330:1287, 1991
18.
Goodnight SH, Coull BM, McAnulty JH, Taylor LM. Antiplatelet therapy: Part I. West J Med158:385, 1993
19.
Goodnight SH, Coull BM, McAnulty JH, Taylor LM. Antiplatelet therapy: Part II. West J Med158:506, 1993
20.
Antiplatelet Trialists' Collaboration.Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ308:231, 1993
21.
Fitzgerald G. Ticlopidine in unstable angina: A more expensive aspirin?Circulation82:293, 1990
Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IlIa complex. J Clin Invest76:101, 1985
27.
Coller BS, Scudder LR. Inhibition of dog platelet function by in vivo infusion of F(ab)*** fragments of a monoclonal antibody to the platelet glycoprotein Ilb/IlIa receptor. Blood66:1456, 1985
28.
Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GBJ. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation84:2463, 1991
29.
Hanson SR, Pareti FI, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest81:149, 1988
30.
Ellis SG, Navetta FI, Tcheng JT, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Feb directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty: An initial experience. Coron Artery Dis4:167, 1993
31.
Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIa receptor to prevent postangioplasty restenosis and thrombosis. J Am Coll Cardiol17:89B, 1991
32.
Simoons ML, Jan de Boer M, van den Brand M, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation89:596, 1993
33.
Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. J Am Coll Cardiol22:381, 1993
34.
The EPIC investigators.Use of a monoclonal antibody directed against the platelet glycoprotein receptor in high-risk coronary angioplasty. N Engl J Med330:956, 1991
35.
Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet343:881, 1991
36.
Imura Y, Stassen JM, Vreys I, Lesaffre E, Gold HK, Collen D.Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost68:336, 1992
37.
Nicolini FA, Lee P, Gaddiel R, Kottke-Marchant K, Topol EJ.Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation89:1802, 1991
38.
Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation89:3, 1993
39.
Riess H. Honing B, vonArnim T, Hiller E.Throm-boxane receptor blockade versus cyclooxygenase inhibition: Antiplatelet effects in patients. Thromb Res42:235, 1986
40.
Gresele P, Amout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis: Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest80:1435, 1987
41.
Hoet B, Falcon C, DeReys S, Amout J, Deckmyn H, Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: A comparison with aspirin. Blood75:646, 1990
42.
FitzGerald GA, Reilly IAG, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation72:1194, 1985
43.
DeClerck F, Beetens J, Van de Water A, Vercammen E, Jansen PAJ. R68070: Thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule, II: Pharmacological effects in vivo and ex vivo. Thromb Haemost61:43, 1989
44.
Yao S-K, Rosolowsky M, Anderson HV, et al. Combined thromboxane A2 synthetase inhibition and receptor blockade arc effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. J Am Coll Cardiol16:705, 1990
45.
Vandeplassche G, Hermans C, Van de Water A, et al. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism. on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ Res69:313, 1991
46.
The RAFT Investigators.Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation89:588, 1994
47.
Serruys PW, Klein W, Rutsch W, et al. PARK: The Post Angioplasty Restenosis Ketanserin trial. J Am Coll Cardiol21:SupplA:322a (abstract) 1993
48.
Knudtson ML, Fliantoft VF, Roth DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol15:691, 1990
49.
Wllerson JT, Yao SK, McNatt J, et al. Liposome-bound prostaglandin E1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation89:1786, 1994
50.
Yao SK, Ober JC, Garfinkel LI, et al. Blockade of platelet membrane glycoprotein ***lb receptor delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation89:2822, 1991
51.
Zahger D, Fishbein MC, Garfinkel LI, et al. VCL. an antagonist of the platelet ***GPlb receptor, markedly inhibits platelet adhesion and intimal thickening following balloon injury in the rat. Circulation92:1269, 1995
52.
Anderson TJ. Meredith IT, Ganz P, Selwyn AP, Yeung AC.Nitric oxide and nitrosovasodilators: Similarities. differences and potential interactions. J Am Coll Cardiol24:555, 1991
53.
Kaul S, Naqvi T, Fishbein MC, et al. Profound inhibition of arterial thrombosis by a novel nitric oxide donor. J Am Coll Cardiol (abstract)34A: 1995
54.
Guide to anticoagulant therapy. American Heart Association. Monograph 1994
55.
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest86:385, 1990
56.
Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4. Circulation89:1523, 1994
57.
Shah PK. Limitations of current thrombolytic therapy and directions for the future. Learning Center Highlights, 1992
58.
Fareed J, Hoppensteadt DA, Walenger JM. Current perspectives on low molecular weight heparins. Sem Thromb Hemosta19(Suppl):1, 1993
59.
Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost47:226, 1982
60.
Marki W, et al. Recombinant hirudin: Genetic engineering and structure analysis. Semin Thromb Hemost17: 1991
61.
Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation79:557, 1989
62.
Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation82:1476, 1990
63.
Kelly AB, Marzec UM, Krupski W, et al. Hirudin interruption of heparin resistant arterial thrombus formation in baboons. Blood77:1006, 1991
64.
Mruk JS. Chesebro JH, Webster MWI, Heras M, Grill DE, Fuster V.Hirudin markedly enhances thrombolysis with rt-PA. Circulation82(Suppl III), 4:135, 1990
65.
Haskel EJ. Prager NA. Sobel BE, Abenschein DR.Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation83:31048, 1991
66.
Webster MWI, Chesebro JH, Grill DE, Badimon JJ, Badimon L, Fuster V. The thrombotic and proliferative response to angioplasty in pigs after deep arterial injury: Effect of intravenous thrombin inhibition with hirudin. Circulation84(Suppl III), 4:2306, 1991
67.
Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Heamostas66:141, 1991
68.
Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Robert WJ.Effectiveness of recombinant desulfathohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation84:232, 1991
69.
Herrman JPR, Walter RM, Hermans JV, Serruys PW.Pharmacological approaches to the prevention of restenosis following angioplasty. [review] Drugs46:18, 1993
70.
Nunes GL, Hanson SR, King SB, Sahatjian RA, Scott NA. Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cardiol23:1578, 1994
71.
Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfato hirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction (TIMI-5 trial). J Am Coll Cardiol23:993, 1994
72.
van den Bos AA, Deckers JW, Heyndricks GR, et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation88[part 1]:2058, 1993
73.
Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease: Safety, half-life, and effect on coagulation parameters. Circulation88[part 1]:2015, 1993
74.
Rigel DF, Olson RW, Lappe RW. Comparisons of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res72:1091, 1993
75.
Buchwald AB. Sandrock D, Unterberg C, et al. Platelet and fibrin deposition on coronary stents in minipigs: Effect of hirudin versus heparin. J Am Coll Cardiol21:249, 1993
76.
Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: A multicenter randomized angiographic trial. Circulation89:1557, 1994
77.
Maraganore JM, Chao B, Joseph ML, et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem264:8692, 1989
78.
Topol El, Bonan R, Jewitt D. et al. Use of direct anti-thrombin, hirulog in place of heparin during coronary angioplasty. Circulation87:1622, 1993
79.
Lidon RM, Theroux P, Lesperance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibi tor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation89:1567, 1993
80.
Antman EM. for the TIMI 9 A investigators. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9 A trial. Circulation90:1624, 1993
81.
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II a investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation90:1631, 1991
82.
Neuhas KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of a randomized trial: r-Hirudin for improvement of thrombolysis (HIT III) study. A study of the Ardeitsgemeinschaft Leitender, Kardiologischer, Koinkenhausarzte (ALKK). Circulation90:1638, 1991
83.
Serruys PW, Deckers JW, Close P. on behalf of the HELVETICA study group. A double-blind randomized, heparin controlled trial evaluating acute and long term efficacy of r-hirudin (CGP 39 393) in patients undergoing coronary angioplasty. (Abstract) Circulation90(Suppl I) I-391, 1993
84.
Schaefer LW, Davidson JT, Vlasuk GP, et al. Antithrombotic efficacy of recombinant tick anticoagulant peptide. Circulation84:1741, 1991
85.
Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation89:1262, 1994
86.
Coller BS, Owen J, Mohr JP, et al. Deficiency of plasma protein S. protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis7:456, 1987
87.
Gruber A, Hanson SR, Kelly AB, et al. Inhibition of throm bus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation82:578, 1990
88.
Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA86:2839, 1989
89.
Haskel El, Tom SR, Day KC, et al. Prevention of arterial re occlusion after thrombolysis with recombinant lipoprotein associated coagulation inhibitor. Circulation84:821, 1991
90.
Reissen R, Isner JM. Prospects for site-specific delivery of pharmacological and molecular therapies. J Am Coll Cardiol23:1234, 1994
91.
Dichek DA. Gene tnnsfer in the treatment of thrombosis. Thromb Haemost70:198, 1993
